Indirect infringement remains a key consideration in patent enforcement, particularly where patented technology is supplied, distributed, or implemented through complex commercial and international supply chains. As products and services increasingly involve multiple parties, questions concerning liability often extend beyond the direct infringer to suppliers, distributors, manufacturers, and other participants involved in the exploitation of a patented invention.
This category covers developments relating to indirect infringement, contributory infringement, and related forms of secondary liability in patent law. Our contributors analyse court decisions, legislative developments, and emerging litigation trends that shape the circumstances under which parties may be held liable for facilitating or enabling patent infringement.
Topics include the supply of essential means, knowledge and intent requirements, component and software-related inventions, online platforms, standard-essential patents (SEPs), and the growing body of case law emerging from the Unified Patent Court (UPC) and national courts. Particular attention is given to decisions that influence enforcement strategies, infringement assessments, and risk management for businesses operating across multiple jurisdictions.
For patent owners, in-house counsel, litigators, and other IP professionals, this section provides timely analysis of one of the most commercially significant and rapidly evolving aspects of patent litigation.
The CoA Karlsruhe held that the fact that a referral is pending before the CJEU regarding the issues of the criteria for raising the FRAND defense (C-170/13 Huawei) does not justify the suspension of…
On February 13, 2015 the Eastern High Court of Denmark issued a decision in an appeal in interlocutory proceedings regarding an application for an interim injunction against the marketing and sale of…
Please click here to find US patent cases from the the U.S. Supreme Court, the US Court of Appeals for the Federal Circuit, and the U.S. Circuit Courts of Appeals with a detailed summary of each case…
Most readers will know that so-called Swiss form claims (“Use of drug X in the manufacture of a medicament for the treatment of disease Y”) were first proposed by the Enlarged Board of Appeal of the …
The newly established 15th Patent Senate of the Appeals Court of Düsseldorf (Presiding Judge Dr. Ulrike Voß) has referred a number of questions concerning the calculation of damages in IP cases to…
by Hetti Hilge
In two recent and surprising decisions the Bundesgerichtshof (German Federal Court of Justice) clarified the effects of a first instance decision nullifying the patent in suit on the…
Before diving into this year’s Oktoberfest with the Munich IP community, colleague contributor Thorsten Bausch summarized the German Federal Court of Justice’s case law of Summer 2014. As the days of…
The Higher Regional Court Düsseldorf has ruled in its decision of 20 March 2014 (docket number 12 W 8.14) that an explicit allegation of entitlement to a national part of a European patent, e.g. by…
The Bolar exemption must be interpreted narrowly in order not to affect the patent holder's exclusive rights. The privilege of the generic drug manufacturers who are allowed to conduct clinical…